Soteropoulos Paula
Director at DNTH; Director at QURE; Chief Executive Officer at AKCEA THERAPEUTICS, INC.
- Sold, on record
- $5.8M
- Dollars the filings state
- Form 4 sales
- 20
- Latest May 8, 2026
- Form 144 notices
- 2
- Proposed sales
- Companies
- 3
- Filed as an executive or holder
Companies
- DNTHDianthus Therapeutics, Inc. /DE/Director
- QUREuniQure N.V.Director
- AKCEA THERAPEUTICS, INC.Chief Executive Officer
Sales by reason
3
Routine
7
Plan not stated
2
No plan
8
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- AKCEA THERAPEUTICS, INC.50,173 shares
- QURE48,578 shares
- DNTH28,792 shares
Shares sold, every Form 4 sale on record.
Timeline
- May 8, 2026Routine
Sold 100% of their holdings
$51k599 shares at $85.47
- Mar 31, 2026Routine
Sold 100% of their holdings
$48k599 shares at $80.11
- Mar 31, 2026Notice
Filed a notice to sell 1,198 shares
$95k1,198 shares
- Mar 24, 2026Routine
Sold 100% of their holdings
$2.2M27,594 shares at $78.05
- Mar 24, 2026Notice
Filed a notice to sell 27,594 shares
$2.2M27,594 shares
- Jun 13, 2024No plan
Sold 9.9% of their holdings
$11k2,220 shares at $5.14
- Jun 16, 2023No plan
Sold 9.2% of their holdings
$43k2,275 shares at $18.99
- Feb 27, 2023Plan not stated
Sold 2.3% of their holdings
$8k384 shares at $19.97
- Jan 18, 2023Unusual
Sold 26.8% of their holdings
$136k6,000 shares at $22.59
- Dec 14, 2022Unusual
Sold 29.3% of their holdings
$159k6,800 shares at $23.44
10 of 22
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | Oct 20, 2026 | RLYB | Director | Exercised or settledOption (Right to Buy) | 3,562 | 0 | SEC | ||
| Oct 16, 2026 | Oct 20, 2026 | RLYB | Director | Exercised options | 3,562 | $2.38 | $8k | 6,544 | SEC |
| May 21, 2026 | May 22, 2026 | DNTH | Director | AwardedStock Option (Right to Buy) | 6,090 | 6,090 | SEC | ||
| May 8, 2026 | May 11, 2026 | DNTH | Director | Sold | 599 | $85.47 | $51k | 0 | SEC |
| May 8, 2026 | May 11, 2026 | DNTH | Director | Exercised or settledStock Option (Right to Buy) | 599 | 0 | SEC | ||
| May 8, 2026 | May 11, 2026 | DNTH | Director | Exercised options | 599 | $8.44 | $5k | 599 | SEC |
| Mar 31, 2026 | Apr 1, 2026 | DNTH | Director | Sold | 599 | $80.11 | $48k | 0 | SEC |
| Mar 31, 2026 | Apr 1, 2026 | DNTH | Director | Exercised or settledStock Option (Right to Buy) | 599 | 599 | SEC | ||
| Mar 31, 2026 | Apr 1, 2026 | DNTH | Director | Exercised options | 599 | $8.44 | $5k | 599 | SEC |
| Mar 24, 2026 | Mar 26, 2026 | DNTH | Director | Sold | 27,594 | $78.05 | $2.2M | 0 | SEC |
| Mar 24, 2026 | Mar 26, 2026 | DNTH | Director | Exercised or settledStock Option (Right to Buy) | 27,594 | 1,198 | SEC | ||
| Mar 24, 2026 | Mar 26, 2026 | DNTH | Director | Exercised options | 27,594 | $8.44 | $233k | 27,594 | SEC |
| May 22, 2025 | May 22, 2025 | DNTH | Director | AwardedStock Option (Right to Buy) | 12,500 | 12,500 | SEC | ||
| May 13, 2025 | May 15, 2025 | RLYB | Director | AwardedOption (Right to Buy) | 28,500 | 28,500 | SEC | ||
| Jun 13, 2024 | Jun 17, 2024 | QURE | Director | Sold | 2,220 | $5.14 | $11k | 20,203 | SEC |
| May 23, 2024 | May 28, 2024 | DNTH | Director | AwardedStock Option (Right to Buy) | 11,000 | 11,000 | SEC | ||
| May 15, 2024 | May 17, 2024 | RLYB | Director | AwardedOption (Right to Buy) | 16,500 | 16,500 | SEC | ||
| Sep 11, 2023 | Sep 13, 2023 | DNTH | Director | AwardedStock Option (Right to Buy) | 6,500 | 6,500 | SEC | ||
| Jun 16, 2023 | Jun 20, 2023 | QURE | Director | Sold | 2,275 | $18.99 | $43k | 22,423 | SEC |
| Jun 13, 2023 | Jun 20, 2023 | QURE | Director | AwardedStock Option (Right to Buy) | 17,060 | 17,060 | SEC | ||
| Jun 13, 2023 | Jun 20, 2023 | QURE | Director | Awarded | 8,700 | 24,698 | SEC | ||
| May 17, 2023 | May 19, 2023 | RLYB | Director | AwardedOption (Right to Buy) | 15,490 | 15,490 | SEC | ||
| Feb 27, 2023 | Mar 1, 2023 | QURE | Director | Sold | 384 | $19.97 | $8k | 15,998 | SEC |
| Jan 18, 2023 | Jan 20, 2023 | QURE | Director | Sold | 6,000 | $22.59 | $136k | 16,382 | SEC |
| Jan 18, 2023 | Jan 20, 2023 | QURE | Director | Exercised or settledStock Option (Right to Buy) | 6,000 | 2,000 | SEC | ||
| Jan 18, 2023 | Jan 20, 2023 | QURE | Director | Exercised options | 6,000 | $5.37 | $32k | 22,382 | SEC |
| Dec 14, 2022 | Dec 15, 2022 | QURE | Director | Sold | 6,800 | $23.44 | $159k | 16,382 | SEC |
| Dec 14, 2022 | Dec 15, 2022 | QURE | Director | Exercised or settledStock Option (Right to Buy) | 6,800 | 0 | SEC | ||
| Dec 14, 2022 | Dec 15, 2022 | QURE | Director | Exercised options | 6,800 | $2.37 | $16k | 20,182 | SEC |
| Nov 29, 2022 | Dec 1, 2022 | QURE | Director | Sold | 6,200 | $25.38 | $157k | 16,382 | SEC |
| Nov 29, 2022 | Dec 1, 2022 | QURE | Director | Exercised or settledStock Option (Right to Buy) | 6,200 | 3,800 | SEC | ||
| Nov 29, 2022 | Dec 1, 2022 | QURE | Director | Exercised options | 6,200 | 22,582 | SEC | ||
| Jun 15, 2022 | Jun 17, 2022 | QURE | Director | AwardedStock Option (Right to Buy) | 17,810 | 17,810 | SEC | ||
| Jun 15, 2022 | Jun 17, 2022 | QURE | Director | Awarded | 9,080 | 16,382 | SEC | ||
| May 24, 2022 | May 26, 2022 | RLYB | Director | AwardedOption (Right to Buy) | 13,440 | 13,440 | SEC | ||
| Feb 28, 2022 | Mar 2, 2022 | QURE | Director | Sold | 596 | $16.87 | $10k | 7,302 | SEC |
| Feb 24, 2022 | Feb 28, 2022 | QURE | Director | AwardedStock Option (Right to Buy) | 2,645 | 2,645 | SEC | ||
| Feb 24, 2022 | Feb 28, 2022 | QURE | Director | Awarded | 1,534 | 7,898 | SEC | ||
| Jan 3, 2022 | Jan 5, 2022 | RLYB | Director | AwardedOption (Right to Buy) | 5,369 | 5,369 | SEC | ||
| Mar 2, 2021 | Mar 4, 2021 | QURE | Director | Sold | 504 | $37.60 | $19k | 6,364 | SEC |
| Feb 25, 2021 | Mar 1, 2021 | QURE | Director | AwardedStock Option (Right to Buy) | 4,107 | 4,107 | SEC | ||
| Feb 25, 2021 | Mar 1, 2021 | QURE | Director | Awarded | 2,382 | 6,868 | SEC | ||
| Feb 27, 2020 | Mar 2, 2020 | QURE | Director | AwardedStock Option (Right to Buy) | 3,620 | 3,620 | SEC | ||
| Feb 27, 2020 | Mar 2, 2020 | QURE | Director | Awarded | 2,063 | 4,486 | SEC | ||
| Feb 5, 2020 | Feb 5, 2020 | QURE | Director | Sold | 2,122 | $60.95 | $129k | 2,423 | SEC |
| Jan 28, 2020 | Jan 30, 2020 | QURE | Director | Sold | 807 | $62.19 | $50k | 4,545 | SEC |
| Jan 7, 2020 | Jan 8, 2020 | QURE | Director | Sold | 3,000 | $72.18 | $217k | 5,352 | SEC |
| Dec 13, 2019 | Dec 17, 2019 | QURE | Director | Sold | 2,000 | $70.50 | $141k | 8,352 | SEC |
| Dec 13, 2019 | Dec 17, 2019 | QURE | Director | Exercised or settledStock Option (Right to Buy) | 2,000 | 9,000 | SEC | ||
| Dec 13, 2019 | Dec 17, 2019 | QURE | Director | Exercised options | 2,000 | $5.37 | $11k | 10,352 | SEC |
Page 1
Sales and notices (22)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | May 11, 2026 | DNTH | Director | Form 4 sale | 599 | $51k | 100.0% | Routine | SEC |
| Mar 31, 2026 | Apr 1, 2026 | DNTH | Director | Form 4 sale | 599 | $48k | 100.0% | Routine | SEC |
| Mar 31, 2026 | Mar 31, 2026 | DNTH | Director | Form 144 notice | 1,198 | $95k | Notice | SEC | |
| Mar 24, 2026 | Mar 26, 2026 | DNTH | Director | Form 4 sale | 27,594 | $2.2M | 100.0% | Routine | SEC |
| Mar 24, 2026 | Mar 24, 2026 | DNTH | Director | Form 144 notice | 27,594 | $2.2M | Notice | SEC | |
| Jun 13, 2024 | Jun 17, 2024 | QURE | Director | Form 4 sale | 2,220 | $11k | 9.9% | No plan | SEC |
| Jun 16, 2023 | Jun 20, 2023 | QURE | Director | Form 4 sale | 2,275 | $43k | 9.2% | No plan | SEC |
| Feb 27, 2023 | Mar 1, 2023 | QURE | Director | Form 4 sale | 384 | $8k | 2.3% | Plan not stated | SEC |
| Jan 18, 2023 | Jan 20, 2023 | QURE | Director | Form 4 sale | 6,000 | $136k | 26.8% | Unusual | SEC |
| Dec 14, 2022 | Dec 15, 2022 | QURE | Director | Form 4 sale | 6,800 | $159k | 29.3% | Unusual | SEC |
| Nov 29, 2022 | Dec 1, 2022 | QURE | Director | Form 4 sale | 6,200 | $157k | 27.5% | Unusual | SEC |
| Feb 28, 2022 | Mar 2, 2022 | QURE | Director | Form 4 sale | 596 | $10k | 7.5% | Plan not stated | SEC |
| Mar 2, 2021 | Mar 4, 2021 | QURE | Director | Form 4 sale | 504 | $19k | 7.3% | Plan not stated | SEC |
| Feb 5, 2020 | Feb 5, 2020 | QURE | Director | Form 4 sale | 2,122 | $129k | 46.7% | Unusual | SEC |
| Jan 28, 2020 | Jan 30, 2020 | QURE | Director | Form 4 sale | 807 | $50k | 15.1% | Plan not stated | SEC |
| Jan 7, 2020 | Jan 8, 2020 | QURE | Director | Form 4 sale | 3,000 | $217k | 35.9% | Unusual | SEC |
| Dec 13, 2019 | Dec 17, 2019 | QURE | Director | Form 4 sale | 2,000 | $141k | 19.3% | Plan not stated | SEC |
| Dec 9, 2019 | Dec 9, 2019 | QURE | Director | Form 4 sale | 11,582 | $752k | 58.1% | Unusual | SEC |
| Apr 8, 2019 | Apr 9, 2019 | AKCEA THERAPEUTICS, INC. | Chief Executive Officer | Form 4 sale | 31,787 | $1M | 100.0% | Unusual | SEC |
| Mar 6, 2019 | Mar 7, 2019 | AKCEA THERAPEUTICS, INC. | Chief Executive Officer | Form 4 sale | 18,386 | $591k | 100.0% | Unusual | SEC |
| Jan 28, 2019 | Jan 30, 2019 | QURE | Director | Form 4 sale | 1,210 | $38k | 5.7% | Plan not stated | SEC |
| Jan 29, 2018 | Jan 31, 2018 | QURE | Director | Form 4 sale | 2,878 | $53k | 13.8% | Plan not stated | SEC |